CAMP4 Therapeutics (NASDAQ:CAMP) Rating Lowered to Sell at Wall Street Zen

by · The Cerbat Gem

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

CAMP has been the topic of a number of other research reports. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Oppenheimer began coverage on shares of CAMP4 Therapeutics in a research report on Monday, October 5th. They issued an “outperform” rating and a $15.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Tuesday, September 29th. Piper Sandler reissued an “overweight” rating and set a $15.00 price target (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Finally, Chardan Capital lowered their price target on shares of CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, CAMP4 Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $10.86.

Get Our Latest Report on CAMP4 Therapeutics

CAMP4 Therapeutics Price Performance

CAMP opened at $3.77 on Friday. CAMP4 Therapeutics has a 52 week low of $2.86 and a 52 week high of $7.75. The stock has a market cap of $236.57 million, a PE ratio of -1.63 and a beta of 0.27. The business has a 50 day moving average of $4.20 and a 200-day moving average of $4.21.

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.34). The firm had revenue of $1.78 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. Equities analysts anticipate that CAMP4 Therapeutics will post -0.66 EPS for the current year.

Insider Buying and Selling at CAMP4 Therapeutics

In other news, Director Andrew J. Schwab sold 400,000 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total value of $1,616,000.00. Following the sale, the director directly owned 2,033,270 shares of the company’s stock, valued at approximately $8,214,410.80. This represents a 16.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kelly Gold bought 10,000 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was bought at an average cost of $3.96 per share, for a total transaction of $39,600.00. Following the completion of the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $39,600. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 46,031 shares of company stock worth $99,051 and sold 593,613 shares worth $2,504,037. 21.69% of the stock is owned by company insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CAMP. Bank of America Corp DE purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth about $78,000. Trails Edge Capital Partners LP purchased a new stake in CAMP4 Therapeutics during the 2nd quarter valued at about $8,446,935. Jupiter Topco LLC purchased a new stake in CAMP4 Therapeutics during the 2nd quarter valued at about $27,581,000. 5AM Venture Management LLC purchased a new stake in CAMP4 Therapeutics during the 2nd quarter valued at about $25,647,928. Finally, BlackRock Inc. bought a new stake in CAMP4 Therapeutics during the 2nd quarter valued at about $7,185,000.

CAMP4 Therapeutics Company Profile

(Get Free Report)

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.

Further Reading